Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055869 | 0.94 | FAAH (0.32) | EHMT2EHMT1PIK3CAPDE4D | |
| SCHEMBL12921298 | 0.87 | MAPT (0.39) | EHMT2EHMT1PIK3CAPDE4D | |
| SCHEMBL10283434 | 0.86 | PDE4D (0.35) | EHMT2EHMT1PDE4D | |
| SCHEMBL12209875 | 0.85 | KDM4E (0.35) | PIK3CAPDE4D | |
| SCHEMBL10265576 | 0.83 | EML4 (0.36) | EHMT2EHMT1PDE4DALOX5EPHX2 | |
| SCHEMBL12209887 | 0.82 | KDM4E (0.34) | EHMT2EHMT1PIK3CA | |
| SCHEMBL12209202 | 0.82 | KDM4E (0.34) | EHMT2EHMT1PIK3CA | |
| SCHEMBL12921371 | 0.82 | — | — | |
| SCHEMBL12921259 | 0.81 | EHMT2 (0.34) | EHMT2EHMT1PDE4D | |
| SCHEMBL974316 | 0.80 | LMNA (0.38) | PIK3CAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | EHMT2 3902/4885EHMT1 3376/4885PIK3CA 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.